Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial

经皮冠状动脉介入治疗 医学 人口 随机对照试验 不稳定型心绞痛 部分流量储备 心源性猝死 心脏病学 急性冠脉综合征 内科学 心肌梗塞 环境卫生 冠状动脉造影
作者
Seung‐Jung Park,Jung‐Min Ahn,Do-Yoon Kang,Sung-Cheol Yun,Young-Keun Ahn,Won-Jang Kim,Chang‐Wook Nam,Jin-Ok Jeong,In-Ho Chae,Hiroki Shiomi,Hsien-Li Kao,Joo‐Yong Hahn,Sung-Ho Her,Bong‐Ki Lee,Tae Hoon Ahn,Ki-Yuk Chang,Jei Keon Chae,David Smyth,Gary S Mintz,Gregg W. Stone
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10438): 1753-1765 被引量:333
标识
DOI:10.1016/s0140-6736(24)00413-6
摘要

Background Acute coronary syndrome and sudden cardiac death are often caused by rupture and thrombosis of lipid-rich atherosclerotic coronary plaques (known as vulnerable plaques), many of which are non-flow-limiting. The safety and effectiveness of focal preventive therapy with percutaneous coronary intervention of vulnerable plaques in reducing adverse cardiac events are unknown. We aimed to assess whether preventive percutaneous coronary intervention of non-flow-limiting vulnerable plaques improves clinical outcomes compared with optimal medical therapy alone. Methods PREVENT was a multicentre, open-label, randomised controlled trial done at 15 research hospitals in four countries (South Korea, Japan, Taiwan, and New Zealand). Patients aged 18 years or older with non-flow-limiting (fractional flow reserve >0·80) vulnerable coronary plaques identified by intracoronary imaging were randomly assigned (1:1) to either percutaneous coronary intervention plus optimal medical therapy or optimal medical therapy alone, in block sizes of 4 or 6, stratified by diabetes status and the performance of percutaneous coronary intervention in a non-study target vessel. Follow-up continued annually in all enrolled patients until the last enrolled patient reached 2 years after randomisation. The primary outcome was a composite of death from cardiac causes, target-vessel myocardial infarction, ischaemia-driven target-vessel revascularisation, or hospitalisation for unstable or progressive angina, assessed in the intention-to-treat population at 2 years. Time-to-first-event estimates were calculated with the Kaplan–Meier method and were compared with the log-rank test. This report is the principal analysis from the trial and includes all long-term analysed data. The trial is registered at ClinicalTrials.gov, NCT02316886, and is complete. Findings Between Sept 23, 2015, and Sept 29, 2021, 5627 patients were screened for eligibility, 1606 of whom were enrolled and randomly assigned to percutaneous coronary intervention (n=803) or optimal medical therapy alone (n=803). 1177 (73%) patients were men and 429 (27%) were women. 2-year follow-up for the primary outcome assessment was completed in 1556 (97%) patients (percutaneous coronary intervention group n=780; optimal medical therapy group n=776). At 2 years, the primary outcome occurred in three (0·4%) patients in the percutaneous coronary intervention group and in 27 (3·4%) patients in the medical therapy group (absolute difference –3·0 percentage points [95% CI –4·4 to –1·8]; p=0·0003). The effect of preventive percutaneous coronary intervention was directionally consistent for each component of the primary composite outcome. Serious clinical or adverse events did not differ between the percutaneous coronary intervention group and the medical therapy group: at 2 years, four (0·5%) versus ten (1·3%) patients died (absolute difference –0·8 percentage points [95% CI –1·7 to 0·2]) and nine (1·1%) versus 13 (1·7%) patients had myocardial infarction (absolute difference –0·5 percentage points [–1·7 to 0·6]). Interpretation In patients with non-flow-limiting vulnerable coronary plaques, preventive percutaneous coronary intervention reduced major adverse cardiac events arising from high-risk vulnerable plaques, compared with optimal medical therapy alone. Given that PREVENT is the first large trial to show the potential effect of the focal treatment for vulnerable plaques, these findings support consideration to expand indications for percutaneous coronary intervention to include non-flow-limiting, high-risk vulnerable plaques. Funding The CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx, a Nipro company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yjw0526发布了新的文献求助10
刚刚
dyf666666完成签到,获得积分10
刚刚
王友完成签到,获得积分10
刚刚
霸气谷雪发布了新的文献求助10
1秒前
1秒前
1秒前
光合谷完成签到,获得积分10
2秒前
慕青的应助被stephenzzz采纳,获得10
2秒前
JIEJIE发布了新的文献求助10
2秒前
秋风的应助被微笑的外绣采纳,获得10
2秒前
JamesPei的应助被快乐的念瑶采纳,获得10
3秒前
高远亮发布了新的文献求助10
3秒前
3秒前
丘比特的应助被finish采纳,获得10
4秒前
空山梦发布了新的文献求助10
4秒前
LL完成签到,获得积分10
5秒前
5秒前
5秒前
半夏发布了新的文献求助10
5秒前
5秒前
彩色口红完成签到,获得积分10
6秒前
NexusExplorer的应助被何靖采纳,获得10
6秒前
111发布了新的文献求助10
6秒前
7秒前
李健的小迷弟的应助被刘婉敏采纳,获得10
7秒前
学阿斗发布了新的文献求助10
9秒前
wuliweiwei发布了新的文献求助10
9秒前
半夏完成签到,获得积分10
10秒前
10秒前
小二郎的应助被chiyudawang采纳,获得10
11秒前
芬枫疯发布了新的文献求助10
11秒前
shitman完成签到,获得积分10
11秒前
传奇3的应助被空山梦采纳,获得10
11秒前
12秒前
安详胜完成签到,获得积分10
12秒前
阿三的应助被潇洒的诗桃采纳,获得30
12秒前
13秒前
tt发布了新的文献求助10
13秒前
科研通AI6.3的应助被霸气谷雪采纳,获得10
13秒前
bean完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178375
求助须知:如何正确求助?哪些是违规求助? 9569182
关于积分的说明 21802781
捐赠科研通 7773247
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556793
邀请新用户注册赠送积分活动 2478346